Johnson & Johnson (NYSE:JNJ) shares advanced 4.96% in last trading session and ended the day at $101.18. JNJ Gross Margin is 69.20% and its has a return on assets of 11.20%. Johnson & Johnson (NYSE:JNJ) quarterly performance is 1.61%.
Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.44, $0.02 better than the analyst estimate of $1.42. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.88 billion.
MetLife, Inc. (NYSE:MET) ended the last trading day at $43.51. Company weekly volatility is calculated as 2.86% and price to cash ratio as 4.73. MetLife, Inc. (NYSE:MET) showed a weekly performance of 1.80%.
MetLife, Inc. (NYSE:MET) announced that it will hold an investor conference on Thursday, Sept. 29, 2016, in New York City. Presenters will include members of MetLife’s senior management team.
On 26 January, Newpark Resources Inc. (NYSE:NR) shares advanced 5.06% and was closed at $4.36. NR EPS growth in last 5 year was 41.40%. Newpark Resources Inc. (NYSE:NR) year to date (YTD) performance is -17.42%.
Newpark Resources, Inc. (NYSE:NR) announced that its Board of Directors has set the date of the Company’s 2016 Annual Meeting of Stockholders. The meeting will be held on Thursday, May 19, 2016 at 10:00 a.m. Central Daylight Time at the Woodlands Waterway Marriott Hotel & Conference Center, 1601 Lake Robbins Drive, The Woodlands, Texas.
ERBA Diagnostics, Inc. (NYSEMKT:ERB) shares advanced 32.63% in last trading session and ended the day at $1.26. ERB Gross Margin is 45.90% and its has a return on assets of -7.00%. ERBA Diagnostics, Inc. (NYSEMKT:ERB) quarterly performance is -37.47%.
The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased ERBA Diagnostics, Inc. (NYSEMKT:ERB) securities between April 14, 2014 and November 20, 2015.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) caters to the Healthcare space. Its weekly performance is 23.33%. On the last day of trading company shares ended up at $0.19. Cytori Therapeutics, Inc. (NASDAQ:CYTX) distance from 50-day simple moving average (SMA50) is -28.47%.
Cytori Therapeutics, Inc. (NASDAQ:CYTX) announced that its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 20th patient (25% of target enrollment). In addition, as per the trial protocol, an independent data monitoring committee has reviewed safety data from the initial 10 patients and recommended that the study continue as planned. The 20 procedures, including the fat harvest from small volume liposuction and the finger injections have all been completed successfully and well tolerated.
Leave a Reply